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A systems study reveals concurrent activation of
AMPK and mTOR by amino acids
Piero Dalle Pezze1,2,3,*, Stefanie Ruf4,5,6,*, Annika G. Sonntag4,*, Miriam Langelaar-Makkinje6, Philip Hall1,2,
Alexander M. Heberle6, Patricia Razquin Navas6,7, Karen van Eunen6, Regine C. To¨lle4, Jennifer J. Schwarz4,8,9,
Heike Wiese9,10, Bettina Warscheid8,9,11, Jana Deitersen12, Bjo¨rn Stork12, Erik Fa¨ler13, Sascha Scha¨uble13,
Udo Hahn13, Peter Horvatovich14, Daryl P. Shanley1,2 & Kathrin Thedieck6,7
Amino acids (aa) are not only building blocks for proteins, but also signalling molecules, with
the mammalian target of rapamycin complex 1 (mTORC1) acting as a key mediator. However,
little is known about whether aa, independently of mTORC1, activate other kinases of the
mTOR signalling network. To delineate aa-stimulated mTOR network dynamics, we here
combine a computational–experimental approach with text mining-enhanced quantitative
proteomics. We report that AMP-activated protein kinase (AMPK), phosphatidylinositide
3-kinase (PI3K) and mTOR complex 2 (mTORC2) are acutely activated by aa-readdition in an
mTORC1-independent manner. AMPK activation by aa is mediated by Ca2þ/calmodulin-
dependent protein kinase kinase b (CaMKKb). In response, AMPK impinges on the
autophagy regulators Unc-51-like kinase-1 (ULK1) and c-Jun. AMPK is widely recognized as
an mTORC1 antagonist that is activated by starvation. We find that aa acutely activate
AMPK concurrently with mTOR. We show that AMPK under aa sufficiency acts to sustain
autophagy. This may be required to maintain protein homoeostasis and deliver metabolite
intermediates for biosynthetic processes.
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T
he serine/threonine kinase mammalian target of rapamycin
(mTOR) is a central regulator of metabolism and cellular
growth, and resides in two multiprotein complexes,
mTORC1 and mTORC2 (refs 1–3) that form part of a wider
signalling network (Fig. 1a). mTORC1 contains the specific
interactors Raptor (regulatory associated protein of mTOR) and
PRAS40 (proline-rich AKT/PKB substrate 40 kDa), whereas
mTOR in mTORC2 specifically binds to Rictor (rapamycin-
insensitive companion of mTOR) and mSin1 (mammalian stress-
activated map kinase-interacting protein 1)1. Comparatively little
is known about mTORC2, which is activated by insulin in
an Akt-independent manner2,4. In contrast, the signalling
cascade via which insulin activates mTORC1 is well described5
and involves the IR (insulin receptor) and IRS1 (insulin
receptor substrate 1), PI3K (phosphatidylinositide 3-kinase),
PDK1 (phosphoinositide-dependent kinase 1), Akt and the
heterotrimeric tuberous sclerosis protein complex (TSC1–
TSC2), consisting of the proteins TSC1, TSC2 and TBC1D7.
TSC1–TSC2 harbours a GTPase-activating protein function
towards the small GTPase Rheb (Ras homologue enriched in
brain). Akt inhibits TSC1–TSC2, which leads to de-repression of
Rheb and activation of mTORC1 at the lysosomes1,3. The best
characterized amino acids (aa) input to the mTOR signalling
network is mediated via the Ragulator-Rag GTPase (Ras-related
GTPase) complex that recruits mTORC1 to lysosomal
membranes, where mTORC1 can be further activated by
insulin5,6. Hence, aa are the primary input to mTORC1 that is
necessary for it to be sensitive to insulin.
mTORC1 activates anabolic processes, including protein
synthesis and inhibits catabolic processes such as autophagy,
which safeguards the cell to maintain protein homoeostasis1,3,5,7.
mTORC1 exerts these effects by phosphorylating several
substrates, including the kinases p70-S6K (ribosomal protein
S6 kinase) and ULK1 (Unc-51-like kinase-1). mTORC1
phosphorylates p70-S6K at threonine 389 (p70-S6K-pT389),
which enhances protein synthesis8. Furthermore, mTORC1 and
p70-S6K exert negative-feedback effects on the IR and IRS,
rendering the IR-PI3K-Akt signalling axis refractory to insulin5.
We refer to the sum of these inhibitory mechanisms as
‘negative-feedback loop’ (NFL). In addition, positive feedbacks
from mTORC1 to IRS have been described9–13.
mTORC1 phosphorylates ULK1 at serine 757 (ULK1-pS757)
to inhibit ULK1-dependent autophagy14,15. Of note, ULK1 is also
phosphorylated by AMPK at S317 (ULK1-pS317), and this event
stimulates ULK1-dependent autophagy14,15. AMPK is typically
considered to be activated by nutrient and energy shortage,
whereas mTORC1 responds to nutrient readdition and insulin.
Therefore, mTORC1 and AMPK are often perceived as
antagonists that suppress or induce autophagy under nutrient
sufficiency or shortage, respectively15. This notion is further
strengthened by the fact that under conditions of low-energy
(high AMP/ATP ratio) AMPK phosphorylates and activates
TSC1–TSC2, thereby inhibiting mTORC1 (refs 5, 15). Yet, it has
been more recently noted that autophagy is also required during
nutrient readdition, to provide aa and metabolite intermediates
for biosynthetic processes16. An activating role of AMPK during
aa stimulation has so far to the best of our knowledge not been
reported, and it remains open whether AMPK sustains autophagy
also during nutrient sufficiency.
In this study, we explored if aa signal exclusively via mTORC1,
or if other mTOR network components respond independently to
aa. As aa activate mTOR in muscle cells, whereas growth factors
appear as a secondary input17,18, we opted for murine C2C12
myocytes as a muscle-related system. We adopted a data-driven
systems approach to build hypotheses on potential further aa
inputs into the mTOR network in an unbiased manner, based on
dynamic time-course data only. For this reason, we started with a
computational network structure, in which we incorporated only
the well-documented direct aa input to mTORC1 (ref. 6). We
built on our earlier modelling work4,19 to test whether simula-
tions of the dynamic network response to aa could match the
measured time-course data, or which additional inputs would
improve the fit between them. Strikingly, a network model
assuming only a single aa input to the network via mTORC1 did
not reproduce our experimental calibration data. In a stepwise
strategy, we added further aa inputs in silico, and additional
network connections via IRS/PI3K, mTORC2 and AMPK
markedly improved the model fit with our experimental data.
We experimentally confirmed these findings and found that aa
acutely activate AMPK via the Ca2þ /calmodulin-dependent
protein kinase kinase b (CaMKKb). We report that under aa
sufficiency, AMPK does not inhibit mTORC1, but sustains ULK1
activity and autophagy.
Results
Modelling predicts multiple aa inputs to the mTOR network.
In the present study, we used computational modelling as a
means of hypothesis building to steer experiments addressing the
regulation of the mTOR network by aa. Our previous model19,
which we used as a starting point, simulated mTOR network
dynamics in response to combined insulin and aa stimulation
(model structure in Supplementary Fig. 1). To integrate aa as a
discrete input, we calibrated our dynamic model with time-course
data from C2C12 myocytes that were stimulated with insulin plus
aa (Supplementary Fig. 2a), or with aa only (Supplementary
Fig. 2b). Cells were lysed at different time points post stimulation
from 1 to 120min, and readouts across the mTOR network
(Fig. 1a) were detected and quantified across at least three
experiments as described4,19. The detected readouts and the core
model structure covered the following signalling connections
(Fig. 1a; additional detail in Supplementary Fig. 1): the insulin
signal is transduced via IR autophosphorylation at Y1146
(refs 20,21), IRS, PI3K and PDK1 that phosphorylates Akt at
T308 (ref. 22). Akt activation, monitored by phosphorylation of
its substrate PRAS40 at T246, inhibits the TSC1–TSC2 complex
by phosphorylation at T1462 (ref. 22); and TSC1–TSC2 inhibits
mTORC1 activity22, as monitored by the phosphorylation of its
substrates PRAS40-S183 and p70-S6K-T389, and the p70-S6K
substrate mTOR-S2448 (ref. 22). Akt-pS473 is the bona fide
mTORC2 activity readout22. Autophosphorylation on mTOR-
S2481 reflects either mTORC1 or mTORC2 activity, depending
on the complex stoichiometries in different cell types4,22,23.
p70-S6K inhibits IRS both by direct phosphorylation at S636/639
and by suppression of IRS gene expression24–26. In addition, we
have recently shown that AMPK is connected to mTORC1 via
another IRS-dependent NFL19. Activation of AMPK, monitored
by phosphorylation of AMPK-T172, inhibits mTORC1 by
activating TSC2 via phosphorylation at S1387 and multiple
phosphorylation of Raptor itself15. We introduced the following
enhancements: we expanded the detail of Akt and PRAS40 to
include all possible combinations of key phosphorylation states.
The TSC1–TSC2 species could be phosphorylated by Akt-pT308
or by AMPK. The former leads to the inactivation of TSC1–TSC2
and activation of mTORC1, whereas the latter promotes
TSC1–TSC2-dependent inhibition on mTORC1. IRS and PI3K
were considered separately to enable simulation of treatment with
the PI3K inhibitor wortmannin. We included two PI3K species,
PI3K_PDK1 that binds IRS and activates Akt, and PI3K_variant
that we have shown to activate mTORC2 in an Akt-independent
manner4 (Supplementary Fig. 1).
We modelled the aa input as directly connected to the network
via mTORC1, which is activated by the Rag GTPases5. The profile
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Figure 1 | Amino acids activate AMPK independently of PI3K. (a) Schematic representation of the mTOR-AMPK network. Amino acids (aa) activate
mTORC1. Do they also activate other parts of the network? Nutrients (aa), growth factors and energy (AMP/ATP ratio) impinge on the mTOR (mammalian
target of rapamycin) signalling cascade. Growth factors such as insulin activate the IR (insulin receptor). The IR binds IRS1 (insulin receptor substrate 1) which
acts as an adaptor for PI3K (phosphoinositide 3-kinase). PI3K generates phosphatidylinositol (3,4,5)-trisphosphate, which binds and translocates PDK1 and
Akt/PKB to the plasma membrane. Here, Akt is activated by PDK1 and subsequently inhibits the heteromeric TSC1–TSC2 (tuberous sclerosis protein)
complex. TSC1–TSC2 serves as a GTPase-activating protein (GAP) for the small GTPase Rheb (Ras homologue enriched in brain) that activates mTORC1.
mTORC1 phosphorylates p70-S6K (p70-S6-kinase), and regulates anabolic processes such as translation and catabolic processes including autophagy.
A negative-feedback loop (NFL) from mTORC1 and p70-S6K to IR and IRS1 renders upstream insulin signalling refractory to the insulin input. AMP levels rise
when energy demand enhances ATP conversion to ADP. AMP and the kinases LKB1 (liver kinase B1), and CaMKKb (Ca2þ/ calmodulin-dependent protein
kinase kinase b) activate AMPK (AMP-activated protein kinase), which inhibits mTORC1 by phosphorylating TSC2 and the mTORC1 component Raptor. Next
to growth factors and the AMP/ATP ratio, aa activate mTORC1, and this is mediated by the Rag GTPases. (b) Simulated response of p70-S6K-pT389,
Akt-pS473, Akt-pT308 and AMPK-pT172 to aa stimulation in a system with PI3K perturbation (PI3K activity 10 to 100%; experimental equivalent: PI3K
inhibition with wortmannin). (c) Aa enhance AMPK-pT172 during PI3K inhibition with wortmannin. Shown are immunoblot results of aa-stimulated C2C12
cells in the presence or absence of 100nM wortmannin. Data are representative of three experiments. (d) Quantitative representations of simulated (PI3K
inhibition: residual activity 10% as shown in b) and experimentally determined dynamics of p70-S6K-pT389, AMPK-pT172, Akt-pS473 and Akt-pT308 upon
stimulation with aa with or without wortmannin. Shown are the mean and s.e.m., N¼ 3. Statistical significance between control and treatment in experimental
quantitations across the time course was detected by repeated measures analysis of variance (ANOVA). Exp Ctrl, experimental control condition (DMSO);
Exp Inhib, experimental PI3K inhibition (wortmannin); Sim Ctrl, simulated control condition; Sim Inhib, simulated PI3K perturbation.
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of the dynamics elicited by combined insulin and aa input was
reflected by simulation with the model based on the established
network structure (Supplementary Fig. 3a). However, simulations
based on this network structure could not match the experimental
data for aa stimulation alone (Supplementary Fig. 3b) which was
particularly evident for AMPK (AMPK-pT172, TSC2-pS1387),
IRS/PI3K (Akt-pT308), Akt (PRAS40-pT246) and mTORC2
(Akt-pS473). The quality of the fit between this model and our
data reported a value of B1,415 using the Akaike information
criterion (AIC)27 (Table 1, single aa input). We speculated that
other network components might respond to aa independently of
mTORC1. Thus, we calculated the AIC after introducing a second
aa input via each network component in addition to mTORC1.
This led to the generation of 12 models, each characterized by a
specific second aa input (Table 1, double aa input). We
considered that a model with n aa inputs represented a
significant improvement with respect to the best model having
n 1 aa inputs, when the AIC of the former was at least 1% less
than the AIC of the latter (black rows in Table 1). This threshold
of 1% was chosen to avoid including solutions that could arise
from numerical approximation in parameter estimation. When
testing models with two aa inputs, we found that the model
Table 1 | Model prediction of multiple amino acid inputs.
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A model with a single amino acid input to mTORC1 was calibrated. Further amino acid inputs were added combinatorially at all levels in the network. For each group of combinations, an amino acid input
was promoted if and only if at least one model containing that input reported an improvement in terms of AIC of at least 1% with respect to the best model of the previous group. AIC, Akaike information
criterion.
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assuming aa inputs on mTORC1 and IRS reported an AIC of
B953, improving the model fit as compared to the model with
one single aa input. The AIC for the models with an additional aa
input at TSC1–TSC2-pT1462, p70-S6K-pT389 or PRAS40-pS183
did not improve by at least 1% (AIC41,401, red text in Table 1),
and these models were consequently discarded. We next
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Figure 2 | mTOR network model with four amino acid inputs and an extended p70-S6K module fits the experimental data. (a) Graphical model of the
mTOR network activated by insulin and four amino acid inputs (Table 1). (b) Comparison between the simulated time courses (solid lines) and the
experimental time courses (points and dotted error bars represent mean and s.e.m.) within 0 to 120min of aa and insulin stimulation. The values on the y
axes are relative intensities that are specific for each readout and cannot be compared among readouts. (c) As in b, in the absence of insulin. Stimulation
with aa only. (d) As in b, in the absence of insulin, in the presence of wortmannin.
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investigated whether a third aa-responsive component could
further improve the fit. This was achieved by testing all the 36
models (Table 1, triple aa input) created by adding third aa inputs
to each model with AIC improvement from the previous group.
We found that the model assuming aa inputs on mTORC1, IRS-p
and mTORC2 showed an AIC ofB798, improving the fit quality
with respect to the best-computed model having two aa inputs. At
this level, most of the model combinations did not present an
improvement (AIC4943, red) with respect to the best model of
the previous group (double aa input to mTORC1 and IRS1-p),
and only seven models obtained an improvement in terms of
AIC. We repeated the procedure considering quadruple aa input
models (Table 1, quadruple aa input) selected from combinations
of these remaining models. We found that only two models
reported an AIC improvement with respect to the best model of
the previous group (AICr790). These two models included aa
inputs on IRS-p, AMPK-pT172 and mTORC2 (AICB680), or
IRS-p, AMPK-pT172 and PI3K_Variant (AICB723), in addition
to the aa input on mTORC1. We focused on the first of these two
models for the following three reasons: (a) no data on the species
PI3K_Variant is currently available, (b) the PI3K_Variant was
modelled as upstream of mTORC2 only and therefore its
aa-dependent activation also propagated the signal to mTORC2
and (c) the first model returned a better fit quality. The complete
definition of the best-fit model (AICB680) is provided in
Supplementary Tables 1–4. The list of the replaced reactions
generating all the intermediate models is shown in
Supplementary Table 3. Details for parameter estimation and
identifiability are reported in Supplementary Table 4,
Supplementary Figs 4–12, and further described in the methods
section.
In summary, the model-based analysis of our data yielded
hypotheses on further aa inputs to the mTOR network via
IRS/PI3K, AMPK and mTORC2 that are not mediated by
mTORC1 (Fig. 1a). When we compared the model simulations
for the network structure with the quadruple aa input to our
experimental data, we found that the simulations qualitatively
reproduced the response dynamics of the mTOR network to
insulin plus aa (Supplementary Fig. 13a), as well as to aa alone
(Supplementary Fig. 13b) for all readouts across the network. We
next investigated the sensitivity of the network to each of the
inputs, beginning with the inputs not mediated by mTORC1.
PDK1 is critical to render p70-S6K PI3K sensitive. To analyse
the contribution of PI3K to mTOR network activation by aa, we
inhibited PI3K by wortmannin. We generated time-course data
following aa stimulation by model simulations (Fig. 1b) and
experiments (Fig. 1c). The simulation predicted aa responsiveness
of the PI3K/PDK1 readout Akt-pT308 and the mTORC2 readout
Akt-pS473, which were strongly suppressed by wortmannin. This
is because the two PI3K variants, which can both be inhibited by
wortmannin, are upstream of PDK1, Akt and mTORC2 (ref. 4).
In contrast, the AMPK response to aa was predicted to remain
largely unaffected by PI3K inhibition (Fig. 1b). These predictions
were confirmed by our experimental data. Whereas Akt-pT308,
and Akt-pS473 inductions by aa were inhibited by wortmannin,
AMPK remained responsive to aa (Fig. 1c,d). Thus, the AMPK
response to aa is not mediated by PI3K.
The simulations correctly reproduced the behaviour of Akt and
AMPK in response to wortmannin, but we noted that the
experimental inhibition of p70-S6K-pT389 by wortmannin was
much more prominent in the experimental data (Fig. 1c) than
predicted by the model (Fig. 1b). A comparison of data obtained
from simulations, and experiments for control and inhibition
with wortmannin at different time points are provided in two
complementary formats: as bar graphs in Fig. 1d and as scatter
and line plots in Supplementary Fig. 14. Bar graphs help draw
attention to the contrast between control and inhibition between
simulation and experiment, whereas the scatter and line format
highlights model fit to data. In either representation, it is clear that
the model predictions for inhibition with wortmannin for p70-
S6K-pT389 are not reproduced in the data, highlighting a poor
sensitivity of the p70-S6K module to PI3K inhibition. Why did our
model correctly reproduce the wortmannin response of Akt, but
not of p70-S6K? Akt and p70-S6K are both AGC kinases that need
to be phosphorylated twice for full activation: by PDK1 within the
so-called T-loop, and by a phosphoinositide-dependent protein
kinase 2 (PDK2) within the hydrophobic motif28. Although the
PDK1 is identical for all AGC kinases, the identity of the PDK2
differs between AGC kinases. In the case of Akt-S473, mTORC2 is
considered the major PDK2, and mTORC1 acts as the PDK2 on
p70-S6K-T389: these connections were both present in our
computational model. However, whereas Akt-pT308 was directly
connected to PI3K, to account for the action of PDK1, there was no
such connection for the PDK1 target site p70-S6K-T229 (ref. 28).
We reasoned that the sensitivity of p70-S6K to PI3K in our model
may be improved with inclusion of this mechanism. Thus, we
added a connection between p70-S6K-T229 and PI3K-PDK1
to our model (Fig. 2a), and we recorded p70-S6K-T229
phosphorylation kinetics (Fig. 1c, quantitation in Fig. 2c,d). For
model calibration, the p70-S6K-pT229 data in response to aa with
and without perturbation by wortmannin were used, in addition to
the full set of kinetic data in response to aaþ insulin, or aa only
(details on parameter estimation and identifiability analysis
provided in Supplementary Tables 5–7, Supplementary Fig. 15
and methods). The comparison between simulations and data for
all readouts across the network revealed a good fit for both the
calibration data sets (Fig. 2b,c) and for the kinetic data upon aa
stimulation that was part of the wortmannin perturbation data set
(Fig. 2d). Comparison of Supplementary Fig. 13b with Fig. 2c
shows that inclusion of the direct PI3K/PDK1-p70-S6K link into
the model decreased the fit for some readouts, such as Akt-pT308,
Akt-pS473 and AMPK-pT172 in response to aaþ insulin. Yet, we
judged it more important that the fit was much improved for
p70-S6K-pT389 (Fig. 2d), as compared with a model without
the PDK1-p70-S6K link (Supplementary Fig. 13c). The simulation
of p70-S6K-pT389 now showed sensitivity to a simulated
PI3K inhibition (Fig. 3a), within the same range as in our
wortmannin experiments (Figs 3b and 1c; Supplementary Fig. 16).
The effects of aa stimulation and wortmannin in terms of increase
or decrease of readouts, including Akt-pT308, Akt-pS473 and
AMPK-pT172, remained consistent between simulations and
measured data across the time course. The model predicted a
gradual reduction for p70-S6K-pT229 upon gradual PI3K
inhibition (Fig. 3a), and this inhibitory effect was confirmed
experimentally (Figs 3b and 1c; Supplementary Fig. 16). The
AMPK-pT172 simulation showed a slight increase upon PI3K
inhibition, possibly as a result of a more pronounced mTORC1-
dependent NFL inhibition. Although the experimental data
recapitulated this tendency, the effect was too small to be stati-
stically significant (Fig. 3b; Supplementary Fig. 16). The conclusion
remained that the AMPK response to aa is not mediated by
PI3K, whereas PI3K mediates aa signals to Akt, mTORC1 and
p70-S6K.
Wortmannin is a broad spectrum PI3K inhibitor that blocks
not only class I PI3Ks, upstream of Akt, but also the class III PI3K
vps34. We used here a wortmannin concentration of 100 nM,
at and below which this inhibitor is specific for class I PI3Ks
(ref. 29); but off-target effects cannot be excluded. Vps34 has been
suggested to mediate a direct stimulatory aa signal to mTORC1
(ref. 30), independently of class I PI3Ks and Akt. To validate if aa
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Figure 3 | Simulations and experiments show that amino acids (aa) activate mTORC1 via the PI3K-Akt signalling axis in an IRS1-independent manner.
(a) Simulated time courses corresponding to the perturbation as shown in Fig. 1b, but using the model including the new p70-S6K extended module. The
simulated time courses for p70-S6K-pT389 and pT229 also incorporate the corresponding experimental data that was used for parameter estimation
(Fig. 1d). The simulated time courses for Akt and AMPK represent predictions using this new model. (b) Equivalent quantitative representations as shown
in Fig. 1d, but using the model including the new p70-S6K extended module. Simulated quantifications are based on data from a of this figure. Experimental
data are the same as shown in Fig. 1d and reported here to compare it with the new model. Statistical significance between control and treatment in
experimental quantitations across the time course was detected by repeated measures analysis of variance (ANOVA). Exp Ctrl, experimental control
condition (DMSO); Exp Inhib, experimental PI3K inhibition (wortmannin); Sim Ctrl, simulated control condition; Sim Inhib, simulated PI3K perturbation.
Shown are the mean and s.e.m., N¼ 3. (c) The allosteric Akt inhibitor MK-2206 reduces mTORC1 activation by aa. Aa-enhanced p70-S6K-pT389 is
reduced upon Akt inhibition with MK-2206, whereas AMPK-T172 remains phosphorylated. Shown are immunoblot results of aa-stimulated C2C12 cells in
the presence or absence of 1 mM MK-2206. Data are representative of three experiments. (d) IRS1 knockdown does not inhibit mTOR signalling upon aa
stimulation. Aa readdition enhances p70-S6K-pT389 and pT229 in control C2C12 myocytes transfected with non-targeting siRNA (siControl) or with IRS1
knockdown (siIRS1). Shown are immunoblot results of aa-stimulated C2C12 cells with and without IRS1 knockdown. Data are representative of three
experiments.
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signalling to mTORC1 requires Akt, we used the allosteric Akt
inhibitor MK-2206 (ref. 31) in combination with aa stimulation
for 5, 15 and 30min (Fig. 3c). MK-2206 inhibited Akt, as
monitored by the reduction of the Akt readouts PRAS40-pT246
and TSC2-pT1462. MK-2206 also inhibited phosphorylation of
the mTORC1 substrate p70-S6K-T389, whereas aa-enhanced
AMPK phosphorylation at T172 remained unaffected. This
suggests that Akt, downstream of class I PI3Ks, indeed mediates
an aa signal to mTORC1, but not to AMPK.
IRS1, upstream of PI3K, not only receives negative-feedback
signals from mTORC1, but also positive-feedback regulation of
IRS1 by mTORC1 has been reported9–13. Hence, mTORC1 could
activate class I PI3K via IRS1 in response to aa. To test this
possibility, we targeted IRS1 by short interfering RNA (siRNA) in
combination with aa stimulation for 5 up to 45min (Fig. 3d). The
knockdown was efficient as monitored by the reduced IRS1 levels.
However, aa-enhanced phosphorylation of the PDK1 substrate
site p70-S6K-pT229, downstream of PI3K, remained unaltered by
the IRS1 knockdown. This suggests that PI3K activation by aa
does not require IRS1, and that positive feedback from mTORC1
to IRS1 does not mediate aa-enhanced class I PI3K signalling in
C2C12 cells. Furthermore, phosphorylation of the mTORC1
substrate p70-S6K-T389 was not reduced in cells without IRS1,
suggesting that IRS1 does not mediate mTORC1 activation by aa.
In summary, we conclude that aa signal to mTORC1 via class I
PI3K and Akt, whereas AMPK activation by aa is PI3K and Akt
independent.
Amino acids activate AMPK independently of mTORC2. We
next analysed if the observed responses of Akt-pS473, Akt-pT308
and AMPK-pT172 to aa were positively connected to each other,
for example, via feedback mechanisms, or if they represent
separate aa inputs to the mTOR network. We inhibited mTORC2
in silico (Fig. 4a) and experimentally (Fig. 4b), using an inducible
mSin1 knockdown (shSin1) C2C12 cell line and recorded time-
course data upon aa stimulation. The model simulation predicted
that if the four inputs (mTORC1, mTORC2, PI3K and AMPK)
were unrelated, mTORC2 inhibition (reflected by a reduction of
Akt-pS473) should not affect aa stimulation of p70-S6K-pT389,
AMPK-pT172 or Akt-pT308 (Fig. 4a). Indeed, we observed that
upon mTORC2 inhibition by shSin1, Akt-pS473 was reduced,
whereas p70-S6K-pT389 and AMPK-pT172 remained responsive
to aa (Fig. 4b,c; Supplementary Fig. 17). In contrast to our
simulation, Akt-pT308 was reduced by mTORC2 inhibition. This
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may be due to the fact that this readout not only reflects PI3K
activity, but that Akt-T308 phosphorylation efficiency depends
also in part on the phosphorylation at S473 (refs 32,33). For
completeness, a comparison between the prediction of the model
without p70-S6K-pT229 module and experimental data upon
mTORC2 inhibition is provided in Supplementary Fig. 18,
showing consistent results.
In summary, the AMPK and mTORC1 responses to aa are not
mediated by mTORC2, whereas we cannot experimentally
exclude an mTORC2 interdependence with the PI3K/PDK1/Akt
axis due to the interdependence of Akt-pS473 (mediated by
mTORC2) and Akt-pT308 (mediated by PDK1). As both
phosphorylation sites depend on PI3K-generated phosphatidyli-
nositol (3,4,5)-trisphosphate binding to Akt, they do not
ultimately allow to distinguish between mTORC2 and PI3K
activity4. Of note, aa have been previously suggested to activate
class I PI3K and mTORC234; however, this study also used Akt-
pT308 and Akt-pS473 as readouts and therefore does not allow a
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conclusion on the interdependence of PI3K and mTORC2
activation by aa.
The finding that AMPK activation by aa is not mediated by the
PI3K/PDK1/Akt axis, or mTORC2 was intriguing as it suggested
that AMPK is activated by aa, and to the best of our knowledge
this activation is not covered in the existing literature. We
validated this finding by stimulating C2C12 cells with two other
combinations of aa in Hank‘s Balanced Salt Solution (HBSS)
medium (Fig. 5a), and observed that these aa mixes also enhanced
AMPK-T172 phosphorylation at 5min post aa readdition,
whereas S6K-pT389 was enhanced later at 15min post aa
readdition. This matched our previous observations (Figs 1c, 2c,
3c and 4b; Supplementary Fig. 2b), and we therefore went on to
investigate AMPK regulation by aa in further detail.
AMPK activation by aa requires CaMKKb. Our simulations and
experiments showed that AMPK acutely responds to aa as early as
1min post aa readdition (Supplementary Fig. 2b). Which
molecular component may mediate such a rapid response?
Although so far not connected to AMPK activation by aa,
CaMKKb had been reported as an AMPK activator in response to
increased cytoplasmic Ca2þ levels15. Therefore, we tested if the
CaMKKb inhibitor STO-609 suppressed AMPK activation by aa,
and indeed STO-609 inhibited aa-stimulated AMPK-T172
phosphorylation (Fig. 5b).
To analyse the possible effect of aa-activated AMPK on the
mTOR network, we inhibited AMPK in silico (Fig. 5c) and
experimentally by STO-609 (Fig. 5d). AMPK-T172 phosphoryla-
tion was suppressed by STO-609 at early time points
post-aa readdition. In contrast, mTORC2 (Akt-pS473), PI3K
(Akt-pT308) and mTORC1 (p70-S6K-pT389) remained aa
responsive when AMPK was inhibited (Fig. 5d). We quantified
the measured readouts and compared them to the simulated
species, which supported our conclusion that inhibition of AMPK
does not affect mTORC1, mTORC2 or PI3K activation by aa
(Fig. 5e; Supplementary Fig. 19). For completeness, a comparison
between the prediction of the model without p70-S6K-pT229
module, and experimental data upon AMPK inhibition is
provided (Supplementary Fig. 20), showing consistent results.
As this finding is central to the present study, we aimed to
confirm it by further experimental set-ups. In C2C12 cells, we
were technically unable to achieve reliable AMPK inhibition by
knockdown or expression of a dominant negative AMPK version.
We therefore switched to another cell type and performed AMPK
knockdown in HeLa cells in combination with an aa time-course
analysis (Fig. 5f, quantitation and statistics in Supplementary
Fig. 21). In line with our results in C2C12 myocytes, we found
that AMPK-T172 phosphorylation was acutely enhanced by aa
readdition. Interestingly, HeLa cells lack LKB1 (liver kinase B1),
which next to CaMKKb is the other bona fide AMPK inducing
kinase15. Thus, LKB1 is dispensable for AMPK activation by aa.
AMPK knockdown in HeLa cells did not affect the readouts of
mTORC2 (mTOR-pS2481) or mTORC1 (p70-S6K-pT389). Thus,
the aa input to AMPK is independent from the ones to mTORC1
and mTORC2. Furthermore, the fact that p70-S6K-pT389 was
not increased by AMPK knockdown (Fig. 5f) or CaMKKb
inhibition (Fig. 5d) suggests that AMPK—upon aa stimulation—
is not a negative regulator of mTORC1, which is in contrast to
other physiological conditions, such as energy or nutrient stress15.
Amino acid-activated AMPK keeps ULK1 and autophagy active.
As mTORC1 remains active when AMPK is activated by aa,
we asked which other AMPK substrates may respond to aa
stimulation. AMPK activates the autophagy-driving kinase ULK1
by phosphorylation at S317 (ref. 14). Thus, we tested if this
phosphorylation can be detected in aa-stimulated C2C12 cells
(Fig. 5g). Indeed, ULK1-S317 phosphorylation was detected both
in starved and aa-stimulated cells, and this phosphorylation was
inhibited by the CaMKKb inhibitor STO-609. This suggests
that upon aa readdition, AMPK sustains ULK1 activity
in a CaMKKb-dependent manner. mTORC1 inhibits ULK1
by phosphorylating ULK1-S757. We found that aa enhanced
ULK1-S757 phosphorylation, and this was insensitive to
CaMKKb inhibition, again validating that mTORC1 activation by
aa is insensitive to the CaMKKb-AMPK signalling axis. As ULK1
phosphorylation by AMPK or mTORC1 has been suggested to be
mutually exclusive in glucose-starved cells14, we tested in
aa-stimulated cells if ULK1 could be still phosphorylated at the
AMPK substrate site (S317), when the mTORC1 substrate
site (S757 in mouse, corresponding to S758 in human) was
phosphorylated (Fig. 5h). For this purpose, we stably transfected
ULK1/2 double-knockout (DKO) mouse embryonic fibroblasts
(MEFs) with either human wild-type ULK1 (ULK1-WT),
or an ULK1 variant in which the mTORC1 substrate site
S758 (corresponding to mouse ULK1-S757) was mutated to
glutamate, to mimic constitutive phosphorylation at this
site (ULK1-S758E). Aa stimulation enhanced ULK1-WT
phosphorylation at the mTORC1 substrate site S758, as
Figure 5 | Amino acids (aa) activate mTORC1, mTORC2 and PI3K independently of AMPK, and phosphorylation of the AMPK substrate ULK1 is
CaMKKb dependent. (a) Different aa mixes enhance AMPK-T172 and p70-S6K-T389 phosphorylation. C2C12 cells were starved in HBSS (16 h), with
subsequent readdition of HBSSþ aa mix 1, HBSSþ aa mix 2 or HBSS only. N¼ 3. aa mix 1: Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, OH-Pro, Ile, Leu, Lys, Met, Phe,
Pro, Ser, Thr, Trp, Tyr, Val; aa mix 2: Arg, Cys, Glu, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, Val. (b) AMPK-pT172 induction by aa is inhibited by the CaMKKb
inhibitor STO-609. Aa-stimulated C2C12 cells were analysed with or without 10mgml 1 STO-609. N¼ 3. (c) Simulated response of p70-S6K-pT389, Akt-
pS473, Akt-pT308 and AMPK-pT172 to aa stimulation and AMPK perturbation (AMPK activity 10 to 100%; experimental equivalent: STO-609). (d) Aa
readdition enhances p70-S6K-pT389, Akt-pT308 and Akt-pS473 in the presence of STO-609. Aa-stimulated C2C12 cells were analysed with or without
10mgml 1 STO-609. N¼4. (e) Quantitative representations of simulated (AMPK inhibition 50%, corresponds to c) and measured dynamics of p70-S6K-
pT389, AMPK-pT172, Akt-pS473 and Akt-pT308 upon aa, with or without STO-609. Shown are the mean and s.e.m., N¼4. Statistical significance between
control and treatment in experimental quantitations across the time course was detected by repeated measures analysis of variance (ANOVA). Exp Ctrl,
experimental control condition (DMSO); Exp Inhib, experimental AMPK perturbation (STO-609); Sim Ctrl, simulated control condition; Sim Inhib, simulated
AMPK perturbation. (f) Aa readdition enhances p70-S6K-pT389, Akt-pT308 and mTOR-pS2481 in cells with AMPK knockdown (siAMPKa1þ 2).
Aa-stimulated HeLa cells were analysed with or without siAMPKa1þ 2 (2 days). N¼ 3. (g) Aa enhance ULK1-pS757 (mTORC1 substrate site), and
ULK1-pS317 (AMPK substrate site) remains phosphorylated. STO-609 reduces ULK1-pS317 but not ULK1-pS757. Aa-stimulated C2C12 cells were analysed
with or without 10mgml 1 STO-609. N¼ 3. (h) ULK1 can be phosphorylated at the AMPK substrate site serine 317, when the mTORC1 substrate site
(ULK1-S758 in human, corresponding to S757 in mouse) is mutated to glutamate (ULK1-S758E). ULK1/2 double-knockout (DKO) mouse embryonic
fibroblasts (MEFs) were left untransfected, or stably transfected with human wild-type ULK1 (ULK1-WT), or ULK1-S758E. N¼ 6. (i) Relative quantitation of
data shown in h. Signals for ULK1-pS317 and ULK1-pS758 in ULK1-WTand ULK1-S758E were quantified and normalized to ULK1 total levels. Values for ULK1-
WT, starvation condition were set to 1. Mean values and s.e.m., N¼6. (j) STO-609 reduces LC3-II autophagy marker levels in aa-stimulated cells.
Aa-stimulated C2C12 cells were analysed with or without 10mgml 1 STO-609. All cells were pre-treated with Bafilomycin A1 (BafA) for 60min. N¼ 3.
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Figure 6 | A phosphoproteomics text mining pipeline identifies c-Jun as an amino acid (aa) target that is inhibited by the CaMKKb-AMPK axis.
(a) Schematic workflow of text mining pipeline. The tools GeNo84 and BioSem86 were used to identify gene and protein text occurrences and associated
molecular events described in available scientific literature (Medline and PubMed Central, PMC). The resulting event list was filtered for joint occurrences
of AMPK and phosphoproteins listed in Supplementary Data 1 and 2 (twofold regulated, see Methods for details). (b) Text mining results. The extrapolated
candidate list contained 2,201 UniProt IDs (Supplementary Data 3). Linguistic preprocessing and filtering of the Medline and PMC open access literature
resulted in 91,264 documents containing either AMPK or one of the phosphoprotein candidates. Molecular event detection by BioSem was broadened to
the full-text range, whenever available through PMC open access. Subsequent filtering for AMPK and one of the candidates occurring as event partners
yielded 47 molecular events. (c) Volcano plot using SILAC ratio of all phosphosites (grey dots) on aa induction at time points 5, 10 and 15min versus
0min. Highlighted in red are phosphopeptides containing the phosphosites S6-pS235/236, c-Jun-pS63 and c-Jun-pS73. Primary aa sequence and
phosphorylation site localization probabilities (in brackets) of the highlighted phosphopeptides are listed in the table. (d) Aa stimulation enhances
S6-pS235/236, c-Jun-pS63 and c-Jun-pS73. Shown are immunoblot results of aa-stimulated C2C12 cells. Data are representative of three experiments.
(e) Aa further enhance c-Jun-pS63 and c-Jun-pS73 when CaMKKb is inhibited by STO-609. Aa-stimulated C2C12 cells were analysed in the presence or
absence of 10 mgml 1 STO-609. Data are representative of three experiments.
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expected (Fig. 5i). For ULK1-S758E-expressing cells, the
anti-ULK1-pS758 antibody did not detect a signal, due to the
mutagenesis. Expression levels of ULK1-S758E were much lower
than for ULK1-WT, leading to a lower ULK1-pS317 signal for the
ULK1-S758E variant. However, when the S317 phosphorylation
signal was normalized to the ULK1 total levels, no reduction in
ULK1-S317 phosphorylation was observed in ULK1-S758E as
compared to ULK1-WT (Fig. 5i). This suggests that in
aa-stimulated cells, ULK1 can be phosphorylated by mTORC1
and AMPK at the same time. ULK1 phosphorylates and inhibits
AMPK35 and we observed that ULK1-S758E expression enhanced
AMPK-T172 phosphorylation, as compared with ULK1-WT
expression (Fig. 5h). This suggests that ULK1-S758E is less active
and that the glutamate mimics an inhibitory phosphorylation. In
the present study, ULK1 was not part of our computational
model, but it will be intriguing to address negative feedback from
ULK1 to AMPK under aa sufficiency in the future.
As ULK1 is inhibited by mTORC1 but activated by AMPK,
leading to inhibition or activation of autophagy, respectively14, we
next asked if AMPK drives autophagy in aa-stimulated cells. For
this purpose, we detected the autophagy marker microtubule-
associated protein 1 light chain 3 (LC3)36 in aa-stimulated C2C12
cells, with or without CamKKb-AMPK inhibition (Fig. 5j).
Unprocessed LC3 (LC3-I) resides in the cytoplasm. During
autophagy, LC3-I is conjugated with phoshatidylethanolamine,
and referred to as LC3-II. In addition, LC3-II is degraded by
lysosomal proteases upon autophagosomal–lysosomal fusion,
decreasing the LC3-II signal. To prevent LC3-II degradation
in the autophagy assay, we added the v-ATPase inhibitor
Bafilomycin A1 (BafA) to all media. BafA blocks
autophagosomal–lysosomal fusion and LC3-II degradation.
Thus, LC3-II accumulation can be reliably detected. In
agreement, BafA treatment enhanced LC3-II in aa-stimulated
C2C12 cells (Supplementary Fig. 22). We stimulated C2C12 cells
with aa for 5–45min, with and without inhibiting the CaMKKb-
AMPK signalling axis by STO-609. As observed previously
(Fig. 5g), STO-609 inhibited AMPK-T172 and ULK1-S317
phosphorylation, but not aa-enhanced phosphorylation of the
mTORC1 substrate site ULK1-S757 (Fig. 5j). Of note, STO-609
treatment significantly reduced the autophagy marker LC3-II
under starvation and 5min aa readdition (Fig. 5j, quantitation
and statistics in Supplementary Fig. 23), suggesting that under aa
sufficiency the CaMKKb-AMPK signalling axis keeps an ULK1
fraction activated and sustains basal autophagy.
The CaMKKb-AMPK axis inhibits c-Jun in aa-stimulated cells.
To comprehensively analyse aa-stimulated phosphorylation
events that depend on AMPK, we adopted a quantitative
phosphoproteomics approach in combination with text mining-
enhanced data analysis. As AMPK responds acutely to aa, we
analysed the phosphoproteome at 5, 10 and 15min upon aa
readdition. 2,517 phosphopeptides containing 2,078 confidently
localized phosphosites were identified. Applying a ratio cutoff of
1.5 and a P-value cutoff of 0.05 (see Methods and Supplementary
Data 1 and 2 for details), 296 phosphopeptides were significantly
regulated at at least one time point (Supplementary Data 1 for
phosphosites, and Supplementary Data 2 for phosphopeptides).
With a twofold cutoff, 108 phosphopeptides remained signi-
ficantly regulated. We continued the analysis with this more
stringent data set. Consistent with a major role of mTOR in aa
signalling, the gene ontology (GO) terms mTOR- and mTORC1-
mediated signalling were significantly enriched (Supplementary
Fig. 24b). To systematically evaluate for each candidate in our
proteomics data set whether it could be regulated by AMPK, we
adopted an automated Medline and PubMed Central (PMC)
wide-text analysis. The text mining pipeline included automated
recognition of genes and proteins in abstracts in Medline, and the
open access subset of PMC full texts (Fig. 6a). We filtered from
the complete text corpus for all abstracts that referenced either
AMPK or at least one of the candidates from our proteomics data
set. As this data set contained Mus musculus UniProt IDs only,
the candidate list was extended with the homologous Homo
sapiens associated UniProt IDs, leading to a total of 2,201 UniProt
IDs (Supplementary Data 3). Linguistic preprocessing and
filtering of the Medline and PMC open access literature yielded
91,264 documents containing at least one of the candidate
UniProt IDs (Fig. 6b). We then employed a molecular event
recognizer and identified events (for example, regulation
relationship between two genes) in abstracts. Molecular event
detection by the BioSem tool was broadened to the full-text range,
whenever available from the PMC open access corpus. Finally, we
filtered for events that mention candidates from our proteomics
data set together with AMPK (Methods), yielding 47 molecular
events. Next to the mTORC1 upstream regulator IRS1 and the
mTORC1 components Raptor (RPTOR) and PRAS40 (AKT1S1),
whose crosstalk with AMPK is known3,19, c-Jun/Jun appeared in
26% of the resulting molecular events (Fig. 6b; Supplementary
Data 3). As c-Jun had to the best of our knowledge not been
previously linked with nutrient stimulation, we decided to further
analyse the response of c-Jun to aa readdition. Two known
activating c-Jun phosphorylation sites were identified with high
confidence in our phosphoproteomic data. Fragment spectra of
the two c-Jun peptides containing either phosphosite are shown
in Supplementary Fig. 24c. We plotted the ratios for all
phosphosites at 5, 10 and 15min aa readdition versus starved
cells as volcano plots, and marked the positions of the two
identified c-Jun phosphosites (Fig. 6c). As a positive control, we
analysed phosphosites of the known mTORC1 downstream
target ribosomal protein S6 (S6)3. S6 is the substrate of
p70-S6K that is upregulated by aa37. As expected, we found
that S6 phosphorylation was increased by aa at all time points.
(Fig. 6c, peptides #3–5). c-Jun phosphorylation at serine 63
(Fig. 6c, peptide #2) was upregulated at all three time points, and
further increased at 10 and 15min of aa readdition. c-Jun
phosphorylation at serine 73 (Fig. 6c, peptide #1) was also slightly
increased B1.54-fold at 15min aa readdition even though
it stayed below the significance threshold. We validated this
observation by immunoblotting and found that both c-Jun-pS63
and c-Jun-pS73 were upregulated by aa stimulation (Fig. 6d). In
agreement with the mass spectrometry (MS) data (Fig. 6c,
peptides #1,2), c-Jun phosphorylation was also in immunoblots
more pronounced at S63 than at S73, and phosphorylation of the
positive control S6 at serine 235/236 was increased (Fig. 6d).
Thus, aa readdition enhances phosphorylation of c-Jun. To test
whether this event is regulated by the CaMKKb-AMPK axis,
we combined aa stimulation with CaMKKb inhibition by
STO-609 and analysed c-Jun-pS63 and pS73 (Fig. 6e). Of note,
STO-609 increased c-Jun phosphorylation, suggesting that
CaMKKb-AMPK activation by aa inhibits c-Jun activity. This
could be mediated by a phosphatase or a kinase that is activated
or inhibited by AMPK, respectively. Interestingly, c-Jun has been
reported to suppress autophagy38, suggesting that c-Jun
inhibition by CaMKKb-AMPK could sustain autophagy under
nutrient sufficiency.
Akt and AMPK remain aa responsive when mTORC1 is inhibited.
The best-described mediator of mTORC1 activation by aa are the
Rag GTPases, and this mechanism is considered independent
of PI3K, AMPK or mTORC25. Nevertheless, regulatory
connections between mTORC1 and AMPK are known (Fig. 1a).
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Therefore, we tested if the newly discovered stimulatory input of
aa on AMPK was mTORC1 dependent or not.
Our model predicted that the aa-responsive components
AMPK, PI3K and mTORC2 remain aa inducible when
mTORC1 is inhibited (Fig. 7a). Our model also suggested
that Akt phosphorylation by PDK1 (Akt-pT308) and mTORC2
(Akt-pS473), as well as AMPK activation are even enhanced
under mTORC1 inhibition. To test this experimentally (Fig. 7b),
we targeted Raptor by shRNA (shRaptor) before aa readdition.
Consistent with our simulations, experimental mTORC1 inhibi-
tion reduced p70-S6K-T389 phosphorylation, and increased
Akt-pS473 and Akt-pT308 as compared with control cells
(Fig. 7b,c; Supplementary Fig. 25). Our simulations also predicted
a moderate and transient activation of AMPK by mTORC1
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Figure 7 | Amino acids (aa) stimulate the mTOR network via cues other than mTORC1. (a) Simulated response of p70-S6K-pT389, Akt-pS473,
Akt-pT308 and AMPK-pT172 to aa stimulation in a system with mTORC1 perturbation (mTORC1 activity 10 to 100%; experimental equivalent: mTORC1
inhibition by Raptor knockdown). (b) Aa readdition enhances Akt-pT308, Akt-pS473 and AMPK-pT172 during mTORC1 inhibition by Raptor knockdown
(shRaptor). Representative immunoblot results of aa-stimulated C2C12 cells with and without shRaptor (4 days). Data are representative of four
experiments. (c) Quantitative representations of simulated (mTORC1 inhibition: reduction to 25%, as shown in a) and experimentally determined dynamics
of p70-S6K-pT389, AMPK-pT172, Akt-pS473 and Akt-pT308 upon stimulation with aa with mTORC1 inhibition using shRaptor. Data are the mean and
s.e.m., N¼4. Statistical significance between control and treatment in experimental quantitations across the time course was detected by repeated
measures analysis of variance (ANOVA). Exp Ctrl, experimental control condition (shControl); Exp Inhib, experimental mTORC1 inhibition (shRaptor); Sim
Ctrl, simulated control condition; Sim Inhib, simulated mTORC1 perturbation. (d) Schematic representation of the mTOR-AMPK network with four aa inputs
(known input green, new inputs magenta). Aa activate (1) mTORC1, (2) PI3K/PDK1, directly activating Akt and p70-S6K, (3) mTORC2 and (4) AMPK via
CaMKKb. Of note, AMPK activation by aa does not inhibit mTORC1, but activates ULK1. mTORC1 inhibits ULK1 in response to aa. Via these events, AMPK
and mTORC1 balance ULK1 activity and autophagy under nutrient sufficiency.
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inhibition at early time points (Fig. 7a) that we observed
in our data at 5 and 10min post-aa stimulation (Fig. 7b,c;
Supplementary Fig. 25), although the effect over the whole time
course was not statistically significant (Fig. 7c; Supplementary
Fig. 25). For completeness, a comparison between the prediction
of the model without p70-S6K-pT229 module, and experimental
data on mTORC1 inhibition is provided (Supplementary Fig. 26),
showing consistent results.
We confirmed our experimental results by a second means of
mTORC1 inhibition using rapamycin. We found that this
mTORC1 inhibitor also reduced p70-S6K-T389 phosphorylation,
whereas AMPK-pT172, Akt-pS473 and Akt-pT308 remained
responsive to aa (Supplementary Fig. 27a,b). In contrast to the
Raptor knockdown (Fig. 7b,c), rapamycin did not enhance Akt
phosphorylation in aa-stimulated cells. Hence, negative feedback
from mTORC1 to Akt is present in aa-stimulated C2C12 cells,
but it is rapamycin insensitive. This is consistent with earlier
reports on rapamycin-resistant mTORC1 functions39,40. The fact
that IRS1 is not required for PI3K and mTORC1 activation by aa
(Fig. 3d) suggests that this negative feedback in aa-stimulated
cells is mediated by molecules other than IRS1. The molecular
mechanism that mediates negative feedback from mTORC1 to
Akt under aa stimulation remains to be determined.
In summary, our data and simulations are consistent with a
model, in which direct mTORC1 activation represents an
important aa input into the mTOR network, which is
supplemented by further, independent inputs activating AMPK,
PI3K/Akt and mTORC2.
Discussion
To date, the aa response of the mTOR network has been
clearly assigned to mTORC1, via the Rag GTPases5, and several
other molecular mechanisms directly impinging on mTORC1
(refs 2,5,30). In this study, we used computational modelling as a
means to broaden the scope and seek other aa inputs to the
mTOR network. There are several other systems modelling
studies of the mTOR network (for example, Jain and Bhalla, 2009;
ref. 41), but only one has attempted to model multiple aa inputs42
and found that a single input via mTORC1 was sufficient to
explain a set of reported observations. Using time-course data
only, our computational strategy for exploring alternative aa
inputs allowed us to comprehensively cover model structures that
showed an improvement to the canonical single aa-mTORC1
input. A total of 70 models were quantified and compared,
offering an exhaustive analysis that provided hypotheses for new
aa inputs. Attesting to the predictive power of our modelling
approach, the model-derived hypotheses steered experiments that
strongly supported the existence of the additional aa inputs into
the mTOR network. Although the branch-n-bound-based
approach taken here proved very effective, the large number of
inputs we considered and the networks they generated were
computationally challenging. The success of our approach
depended on an effective strategy for model selection together
with reliable and efficient tools for parameter estimation and
identification. Discovery phosphoproteomics complemented by
computational large-scale text mining strategies proved a
powerful means to expand the predictions arising from our
small-scale dynamic model simulations to an omics-wide level
and to systematically cover the full body of available scientific
literature. The issue of how to expand small-scale dynamic
modelling approaches to an omics-wide level is one of the major
challenges in systems biology. Genome scale models allow to deal
with large data sets, but do not offer the level of detail necessary
for dynamic signalling network analyses as done in this study.
Our final computational model predicted additional,
independent aa inputs to the network via AMPK, mTORC2
and class I PI3K upstream of Akt and mTORC1 (Fig. 7d). In the
light of mTORC1 being considered as the central p70-S6K
activator upon aa, we were surprised by the strong, direct
dependence of p70-S6K-pT389 on PI3K/PDK1 (Fig. 1). The
requirement of this link for the reproduction of the measured
data by our model highlights the critical importance of the PDK1
input to p70-S6K in response to aa. In support of this notion, a
recent study has reported the requirement of PDK1 for mTORC1
and p70-S6K activation by leucine in cardiac myocytes43.
Strikingly, AMPK responded acutely and within 1min to aa,
and its activation was independent of the other aa-responsive
components mTORC2, PI3K and mTORC1. This suggests
aa as novel metabolic activators of AMPK. This finding was
unexpected because AMPK is mainly considered to be activated
by stress and starvation conditions, including aa withdrawal44
although there is conflicting data45. This may in turn imply that
aa exert an inhibitory effect on AMPK, which has indeed been
suggested by several studies46–48. It should be noted though that
all these studies observed AMPK phosphorylation at the earliest
at 15min post aa addition. At this time point we also observed
AMPK repression (Supplementary Fig. 2b), and this is why
the earlier studies may have missed the early AMPK inducibility
by aa.
How is the aa signal transduced to AMPK? LKB1 is the most
commonly reported activating kinase for AMPK that phosphor-
ylates AMPK in the activation loop at T172 (ref. 15). However,
AMPK responded to aa not only in C2C12, but also in HeLa cells
(Fig. 5f) that lack LKB1 (refs 49,50). Therefore, we tested the
impact of CaMKKb, another kinase for AMPK15, which had been
shown in an earlier study to mediate AMPK phosphorylation in
response to the glutamate agonist homocysteine sulfinic acid45.
We found indeed that CaMKKb inhibition prevented AMPK
activation by aa. Of note, CaMKKs have also been shown to act as
upstream regulators of the Akt pathway in non-muscle cells51,
but this was not the case in aa-stimulated C2C12 cells (Fig. 5d,e).
The CaMKKb mediated AMPK activation involves an increase in
intracellular Ca2þ without requiring a change in AMP or ADP
levels52. Ca2þ release typically happens on very short time scales,
which is in agreement with the observed rapid response of
AMPK to aa. Aa have been reported to allosterically activate
extracellular calcium receptor (CaR) proteins53. CaR belong
to the G-protein-coupled receptor family. CaR are able to
activate intracellular signalling molecules, including cytosolic
phospholipase A2 (ref. 54) and mitogen-activated protein
kinases55 via CaMKKb. Thus, AMPK may be another kinase
that is activated by aa-sensitive CaR via CaMKKb.
Our data suggest that activation of the CaMKKb-AMPK
axis by aa does not inhibit mTORC1 (Fig. 5d,f,g), but
sustains ULK1 activity and autophagy (Fig. 5g,j). Likewise,
c-Jun, reported to respond to AMPK56 and to inhibit
autophagy38, was phosphorylated upon aa readdition (Fig. 6d),
and hyperphosphorylated when CaMKKb was inhibited (Fig. 6e).
Aa readdition activates mTORC1-dependent translation57, which
is generally perceived as being associated with an inhibition of
autophagy58. Why may cells activate autophagy in response to
nutrient readdition? It has been noted recently that activation of
biosynthetic pathways may require autophagy for several reasons.
Firstly, increased protein synthesis inevitably also increases
the amount of misfolded proteins59, and autophagy contributes
to their clearance60. Secondly, the upregulation of biosynthetic
processes requires increased amounts of metabolite intermediates,
which are provided by autophagy as well16. Consistent with this,
a previous study described active autophagy in the context of
active mTORC1 signalling61.
In this study, we have analysed the global effect of a mixture of
aa on the mTOR signalling network. Thus, we did not
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differentiate between the relative contributions of different aa to
AMPK activation. Future efforts will need to focus on the relative
contribution of different aa to this event. Here, the branched-
chain aa leucine, as well as glutamine and arginine deserve
particular attention, as they all have been identified as being
important in the regulation of the mTOR network5,62,63.
Methods
Cell lines and tissue culture. Experiments were performed in C2C12 myoblasts
(obtained from the department of Ralf Baumeister, University of Freiburg, D4,19),
HeLa a Kyoto cells (obtained from Cecile Arrieumerlou, University of Basel,
CH 64) and Ulk1/2 DKO MEF cells (kindly provided by Tullia Lindsten,
Memorial Sloan Kettering Cancer Center, New York City, USA) overexpressing
FLAG-ULK1-WT or FLAG-ULK1-S758E. All cells were tested every 3 months for
mycoplasma contamination by performing a PCR on the cell supernatant65.
For retroviral infection of MEFs, human complementary DNAs encoding either
FLAG-tagged full-length ULK1 or an ULK1-S758E mutant were cloned into
pMSCVpuro (Clontech Laboratories, Takara Bio, 631461). For the production of
recombinant retroviruses, Plat-E cells (kindly provided by Toshio Kitamura,
Institute of Medical Science, University of Tokyo, Japan) were transfected with
1.9 mg pMSCVpuro-based retroviral vectors using FuGENE 6 transfection reagent
(Roche, 11988387001). Ulk1/2 DKO MEF cells66 were incubated with retroviral
supernatants containing 9 mgml 1 Polybrene (Sigma-Aldrich, H9268-106)
and were selected in medium containing 2.5 mgml 1 puromycin (InvivoGen,
ant-pr-1). For inducible knockdown of mSin1, C2C12 cells were transduced with
lentivirus encoding the specific shRNA (target sequence: 50-TAATCCAAAACTT
AGTGCT-30) on the tetracycline-sensitive pTRIPZ vector (clone V3THS_375315)
obtained from Dharmacon Thermo Fisher Scientific, Waltham, MA, USA. C2C12
cells were transduced with lentivirus according to the manufacturer’s instructions.
Knockdown was induced with 2 mgml 1 doxycycline (Calbiochem, Merck,
Darmstadt, Germany) for 4 days. For knockdown of Raptor, a lentiviral plasmid
was obtained from Addgene (pLKO mouse shRNA 2 raptor, #21340, target
sequence: 50-CCGGGCCCGAGTCTGTGAATGTAATCTCGAGATTACATT
CACAGACTCGGGCTTTTTG-30). C2C12 cells were transduced with viral
supernatant twice. Cells were collected 4 days after the first transduction.
AMPKa1/2 siRNA (human, sc-45312) was purchased from Santa Cruz
Biotechnology, Santa Cruz, CA, USA and IRS1 siRNA (mouse, L-040503-02-0005)
was purchased from GE Healthcare, Dharmacon. HeLa a Kyoto cells were
transfected with 10–20 nM siRNA and Lipofectamine 2000 (Life Technologies,
Carlsbad, CA, USA) for 48 h according to the manufacturer’s instructions.
Antibodies and reagents. The anti-GAPDH monoclonal antibody (AB8245) was
obtained from Abcam, Cambridge, UK and used at a final dilution of 1:10,000 in
TBST (tris-buffered saline-Tween) buffer (138mM sodium chloride, 2.7mM
potassium chloride, 66mM tris (pH 7.4), 0.1% Tween-20) with 5% bovine serum
albumin (BSA). BSA (K45-001) was obtained from GE Healthcare. The antibody
recognizing insulin receptor b (sc-711) was purchased from Santa Cruz Bio-
technology and used at a final dilution of 1:1,000 in TBST buffer with 5% BSA.
Horseradish peroxidase conjugated goat anti-mouse (#31430) and goat anti-rabbit
(#31460) IgG were obtained from Pierce Biotechnology (Thermo Fisher Scientific,
Rockford, IL, USA) and used at a final concentration of 0.1 mgml 1 in TBST
buffer with 5% BSA. The rabbit polyclonal antibody against p70-S6K (phospho
T229, GTX25231-50) was obtained from Biozol, Eching, Germany and used at a
final dilution of 1:1,000 in TBST buffer with 5% BSA. All other antibodies were
obtained from Cell Signaling Technology, Danvers, MA, USA as described
previously4,19. In addition, ULK1-pS371 (#6887), ULK1-pS757 (#6888), ULK1
(#8054), c-Jun-pS63 (#9261), c-Jun-pS73 (#9164), c-Jun (#9165), S6-pS235/236
(#4856) and S6 (#2317) antibodies were purchased from Cell Signaling Technology.
All antibodies from Cell Signaling were used at a final dilution of 1:1,000 in TBST
buffer with 5% BSA. Rapamycin (R8781) and wortmannin (W1628) were supplied
by Sigma Aldrich, St. Louis, MO, USA. MK-2206 (S1078) was purchased from
Selleckchem, Houston, TX, USA. STO-609 (sc-202820) was purchased from Santa
Cruz Biotechnology. BafA (#88899-55-2) was supplied by bioaustralis, Smithfield,
NSW, Australia. Chemicals were purchased from Carl Roth, Karlsruhe, Germany if
not indicated differently.
Analysis of cell lysates. Cells were starved, stimulated and lysed as described
previously19. In brief, cells were starved for aa and growth factors in HBSS for 16 h
before all stimulation experiments. Cells were stimulated with DMEM containing
aa and supplemented with 100 nM insulin (I1882, Sigma Aldrich) or with DMEM
only, as indicated. For HBSSþ aa stimulation experiments, different aa mixtures
were obtained from Sigma Aldrich (catalogue number aa mix 1: R7131 and aa mix
2: M5550) and added 1:50 to HBSS medium. In addition, L-glutamine was added to
a final concentration of 3mM (#25030081, Gibco, Life Technologies). Cells were
lysed in RIPA lysis buffer (150mM sodium chloride, 50mM Tris [pH 8.0], 1%
NP40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with Complete
(#11836145001, Roche, Mannheim, Germany), Phosphatase Inhibitor Cocktail 2
(P5726), Phosphatase Inhibitor Cocktail 3 (P0044) (both Sigma Aldrich).
Rapamycin (100 nM), wortmannin (100 nM), MK-2206 (1 mM) or STO-609
(10 mgml 1) were added 30min before and during the stimulation with
DMEM. BafA (100 nM) was added 60min before and during stimulation
with DMEM. Inhibitors were dissolved in dimethyl sulfoxide (DMSO), and
controls were treated with DMSO only.
Pierce enhanced chemiluminescence (ECL) western blotting substrate (#32209)
or SuperSignal West Femto (#34095), both Thermo Scientific Pierce were used to
detect chemiluminescence using a LAS-4000 mini camera system (Fujifilm Life
Science Systems; Figs 1c, 4b, 5b, 5f and 7b; and Supplementary Figs 2 and 27a) or
LAS-4000 mini camera system (GE Healthcare; all other figures). To detect several
proteins of different molecular weights on one membrane, the molecular weight
of each protein was determined using the protein all blue standard marker
(#161-0393, Bio-Rad, California, USA), and membranes were cut accordingly.
The uncropped immunoblots for all figures and Supplementary Figures are shown
in Supplementary Figs 28–39.
For graphical representation, raw images taken with the Fujifilm camera were
exported as colour TIFF files using the Fujifilm software Multi-Gauge version 3.0,
Fujifilm Life Science Systems, and further processed with Adobe Photoshop version
CS2. For quantitation, the raw images were analysed with Multi-Gauge version 3.0
software (Fujifilm). Local background was subtracted.
Raw images taken with the LAS-4000 mini system were exported as red green
blue (RGB) colour TIFF files using ImageJ, and further processed with Adobe
Photoshop version CS5.1. Quantitation of raw image files was performed using
ImageQuant TL Version 8.1, GE Healthcare. The rolling ball method was used for
background subtraction, and the radius was set to 200.
The obtained values were normalized to the control condition and loading control.
The mean and the s.e.m. were plotted and statistics calculated as described below.
Mathematical model. The final model including the extended p70-S6K module
consisted of 31 species and 48 mass-action reactions and was built using ordinary
differential equations (ODEs). The species and reactions described the phosphor-
ylation and dephosphorylation protein states of the following modules: IR, IRS,
PI3K, Akt, AMPK, TSC1–TSC2, PRAS40, mTORC1, mTORC2 and p70-S6K. The
initial protein amount of the unphosphorylated states was fixed a priori to a value
that avoided phosphorylation level saturation, whereas the initial amount for the
phosphorylated states was fixed to 0. The low basal network activity under
starvation is neglected by this simplification. The model was linked to immunoblot
experimental data by 12 observable variables (Supplementary Tables 1 and 5)
covering all the network. The observable variables used for model parameter
estimation and as readouts (model output) throughout the manuscript are
indicated with the suffix ‘obs’ in the model files. For the species Akt, PRAS40
and p70-S6K, the observables represented the total phosphorylation level of the
corresponding phosphosite (for example, Akt-pS473-obs was associated to the sum
of the species Akt-pS473 and Akt-pT308-pS473, whereas Akt-pT308-obs was
linked to the sum of the species Akt-pT308 and Akt-pT308-pS473). Although this
design represented all Akt, PRAS40, and p70-S6K phosphorylation states, its
expansion was combinatorial in the number of states, adding complexity to the
parameter estimation and identification. Using an approach similar to rule-based
modelling67, we constrained the parameter values of the corresponding first and
second reactions (for example, the parameter Akt-pS473-dephos-first, which
regulated the dephosphorylation from the state Akt-pS473 to Akt, was constrained
to be equal to the parameter Akt-pS473-dephos-second, which regulated the
dephosphorylation from the state Akt-pT308-pS473 to Akt-pT308). This process
allowed us to express all the internal states of Akt and PRAS40, but maintained a
low number of estimated parameters. A legend of all the names (for example,
species, parameters, observables and so on) used in the model is provided in
Supplementary Tables 1 and 5. A complete list of ODEs is provided in
Supplementary Tables 2, 3 and 6.
The Matlab Toolbox PottersWheel68 and the PottersWheel identifiability
toolboxes MOTA69 and PLE70 were used for designing and calibrating the kinetic
rate constants of the models. Each reaction contained a kinetic rate constant
parameter that was estimated within the range (1e 06, 1eþ 04). The insulin
receptor module (three parameters) was independently calibrated by executing two
rounds of combined parameter estimation and MOTA identifiability analysis
(Supplementary Table 4; Supplementary Fig. 4). Each round consisted in up to
2,500 independent fits with a parameter disturbance noise of 0.4. For each fit a
maximum of 250 iterations with w2 and parameter tolerances of 1e 05 were run
using the TrustRegion optimization algorithm. For each round, parameters were
considered as non-identifiable when their correlation coefficient of the parameter
tuple and the coefficient of variance were 415% and 0.9%, respectively. Since the
s.e. of the experimental time points was often large, a 10% error model of
observation was adopted solely for the task of parameter estimation. This improved
the approximation of the model versus the data. CVODES integrator was selected
and configured with the following parameters: maximum number of steps,
1,500; relative tolerance, 1e 06; and absolute tolerance, 1e 08. MOTA was
configured with the parameters: percentageBestFits, 50; minimumPValue, 0.001;
percentageOutliers, 100; maxNumberOfParameters, 5. Once the IR was calibrated,
the networks (from 32 to 35 parameters) for the 69 model variants, including
additional aa inputs, were estimated maintaining the previous algorithm
configuration. To reduce the computation time of this task, a cluster of six
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GNU/Linux computers for a total of 60 cores was adopted. For the model including
the aa input connections of mTORC1, mTORC2, AMPK and IRS, and the
simplified p70-S6K module (Supplementary Tables 1–4), we estimated and
identified the parameters by iterating up to eight rounds of alternated parameter
estimation and MOTA identifiability analysis (Supplementary Table 4;
Supplementary Figs 4–12). Due to the difficulty of measuring PI3K dynamics
experimentally, the PI3K module was not associated to any observable data.
Therefore, the parameters describing this protein complex were assumed during
the calibration of the model, including a simplified p70-S6K module, to limit
parameter non-identifiability. We opted to set these parameter values so that the
time course profile for PI3K was close to that for IR. This model was then enhanced
to incorporate a more accurate design for the p70-S6K module. To limit the
computation time and still achieve an accurate solution, we did not estimate the
model entirely, but rather used most of the results from the previous computations
(IR and eight additional calibration rounds Supplementary Table 4), but estimated
all the eight parameters defining the new p70-S6K module and re-estimated the
main four parameters affected by the NFL (IRS, PI3K). The estimation of the
parameters for PI3K was considered at this stage to further improve the p70-S6K-
dependent NFL. As again, we did not need to re-estimate all the parameters the
solution space was sufficiently constrained and limited. In fact, the parameters for
PI3K were not completely free as would have been the case for the original cali-
brations of the rounds 1–8, but were indirectly constrained to the dynamics of Akt,
IR and IRS, whose parameters were fixed. This approach allowed us to estimate all
these 12 parameters within two additional rounds of parameter estimation.
PLE identifiability analysis was performed a posteriori based on the parameter
values of this final model. Almost all the parameters were structurally and
practically identifiable except for eight parameters labelled as practically
non-identifiable (Supplementary Tables 4 and 7). However, we observed that these
either involved parts of the network of secondary importance to our study, such as
the refractory state of the IR or PRAS40-T246, or phosphatases for which we did
not have any measurement, such as the dephosphorylation of
Akt-pT308 or TSC2-pT1462. In addition to the final value of each parameter,
we also computed the mean and s.d. from the selected round fits, to assess
parameter variability in relation to the model and not only to individual parameter
perturbation. In conclusion, we provided evidence that all the model components
required for determining our predictions are identifiable.
Modelling Tasks. Copasi 4.8.35 (ref. 71) was used for simulating the inhibition
experiments for 10 levels of protein from 10 to 100% (control) for mTORC1,
mTORC2, PI3K and AMPK. As the total level of these proteins remains constant
across the time course, this was achieved by modifying initial amounts. Simulations
were calculated by running a deterministic algorithm (LSODA), which was
configured with the following parameters: duration, 120; interval size, 0.1; intervals,
1,200; integrate reduced model, 0; relative tolerance, 1 10 6; absolute tolerance,
1 10 12; and maximum internal steps, 10,000. PottersWheel was used to export
the models in SBML format72 Level 2 Version 4. CellDesigner 4.3 (ref. 73) was used
to construct the model network topology in systems biology graphical notation
(SBGN)74.
Quantitative SILAC-based phosphoproteomics. Two triple-SILAC approaches
were combined to analyse the phosphoproteome of C2C12 cells upon aa stimu-
lation for 0–30min. Cells were starved for aa for 16 h, before aa readdition. The
first approach covered 0, 5 and 30min aa stimulation. For the second approach 10,
15 and 30min time points were chosen. Measurements at the 0min time point
(that is, no aa readdition) were used as a reference point for no induction. The fact
that the 30min time point was used for both settings allowed the normalization to
this time point and thus a quantitative phosphoproteome analysis across five time
points. C2C12 cells were cultivated in SILAC media containing either non-labelled
arginine and lysine (light), 13C6-arginine/D4-lysine (medium) or 13C615N4-arginine/
13C615N2-lysine (heavy) for at least five passages (1:10), then starved for aa
and growth factors for 16 h followed by a stimulation with aa for five different
time points. Cells were lysed in sodium deoxycholate lysis buffer and lysates
were mixed 1:1:1 followed by tryptic digestion using a trypsin-to-protein ratio
of 1:50 at 37 C for 6 h. In total, five experiments were performed with label
switches between the various time points to avoid bias toward a particular label.
Zero and 5min time points included three biological replicates, 10 and 15min
included two biological replicates, while the time point 30min was included in
all experiments and served as normalization. The experimental design of the
proteomics study is outlined in the legend sheet of Supplementary Data 1 and 2.
The distribution of the SILAC ratios for the data sets acquired at 5, 10 and 15min
of aa stimulation is presented in Supplementary Fig. 24a. The SILAC ratio
distribution was highly similar across all three time points, as only a small fraction
of all measured phosphosites changed in abundance, whereas the central part
remained constant.
Strong cation exchange chromatography and titanium dioxide enrichment were
essentially performed as described75,76. In brief, 30 fractions a 2.1ml were collected
throughout the strong cation exchange chromatography gradient. A measure of
20ml of each fraction were directly used for liquid chromatography/MS analysis,
while the major part of the fractions was subjected to titanium dioxide enrichment.
All samples were desalted as described77. Liquid chromatography/MS analysis was
performed on an LTQ Orbitrap XL (Thermo Fisher Scientific, Bremen, Germany)
either coupled to an Agilent 1200 or an Eksigent 2D nanoflow-high-performance
liquid chromatography equipped with in-house packed C18 columns of about
20 cm length (Reprosil-Pur 120 C-18-AQ, 3 mm, Dr Maisch, Ammerbuch,
Germany) and no pre-column was used. Peptides were separated using a binary
solvent system consisting of buffer A (0.5% acetic acid) and buffer B (0.5% acetic
acid and 80% acetonitrile). Samples were loaded in 2% buffer B with a flow rate of
500 nlmin 1 and separated by a gradient from 2 to 35% buffer B in 100min,
followed by a gradient from 35 to 80% in 20min with a flow rate of 250 nlmin 1.
Mass spectrometric measurements were performed in the data-dependent
mode. The spray voltage was 2.3 kV with no sheath or auxiliary gas flow. The
ion-transfer tube temperature was set to 200 C. MS spectra in the range of m/z
350–2,000 were acquired using an automatic gain control of 1 106. The five most
abundant multiply charged peptides were selected for fragmentation in the linear
ion trap using 35% collision energy and an automatic gain control of 5,000.
Multistage activation was enabled with a list for neutral losses of one, two and three
phosphoric acid masses. Dynamic exclusion of previously selected m/z values was
enabled with a duration of 45 s and an isolation width of 2.
Raw MS files were processed using MaxQuant 1.3.0.0 (refs 78,79) and the
UniProt mouse protein sequence database (2013.10, containing 51,219 protein
sequences)80. Parameters of MaxQuant processing and raw and processed files
were uploaded to ProteomeXchange81 (identifier: PXD003073).
The MaxQuant protein and modified peptide identification summary was
obtained from the ‘modificationSpecificPeptides.txt’ MaxQuant output file, and the
quantitative phosphorylation sites data from the ’Phospho(STY)Sites.txt‘ file,
which have been uploaded to ProteomeXchange (see Data availability). MaxQuant
output files are provided in Supplementary Data 4. These data were processed with
a custom Matlab script that was submitted together with the raw and processed
files to ProteomeXChange. The significantly regulated phospho(STY)sites and
phosphopeptides resulting from the Matlab processing are presented in
Supplementary Data 1 and 2, respectively. In brief, the Matlab script calculated all
possible ratios between 5, 10 and 15min as nominator and 0min as denominator
leading to nine and six ratios for time points of 5, 10 and 15min, respectively, using
the intensity columns of the three label variants according to the experimental
design (see experimental design description in Supplementary Data 1and 2). All
log2 ratios were corrected with the log2 ratios median and the entries with at least
two existing or non-zero ratios were selected for Volcano filtering. The fold change
and one sample t-test with null hypothesis that log2 fold ratio is 0 were calculated
for the filtered data for Volcano plot visualization. Filtering of the data was
performed with threshold of 1.5 and 2 for fold change and t-test P-value of 0.05
without correction for multiple testing. In data obtained by MaxQuant, we
assumed that phosphosites with a probability 40.75 are correctly localized.
Text mining. Supplementary Data 1 (phosphosites) and 2 (phosphopeptides) list
the twofold-regulated phosphoproteins for which known molecular links (termed
‘molecular events’) with AMPK were sought. Molecular events comprise protein
production and breakdown, localization, binding as well as positive and negative
regulatory events as defined in the BioNLP Shared Task 2011 on Event
Extraction82. To mine the scientific literature in an automated manner, Medline as
well as the open access subset of PMC were linguistically preprocessed. As of
December 2015, Medline comprised 24 million abstract entries and the open access
subset of PMC 1 million full-text entries.
The tools utilized for linguistic preprocessing were taken from the JCore
repository, and comprise segmentation of text into basic units (sentences and
words), acronym recognition and grammatical analysis required for subsequent
text mining tools (for example, part of speech tagging)83. Next, a semantic analysis
to correctly identify the occurrence of genes and proteins in texts, as well as
molecular events between those was carried out. The identification of gene and
protein name occurrences, as well as the assignment of an appropriate UniProt
identifier was accomplished by the GeNo tool84. Using UniProt IDs for each
identified gene or protein name ensured the unique and canonical identification of
the referenced entity and thus served as a disambiguation facility. This
normalization step was necessary, because the same name may be used to denote a
set of distinct genes or proteins. Before conducting the analysis for events, the
Medline and PMC databases were filtered to allow for efficient computability.
The filtering was done by identifying those Medline abstracts that contained either
an occurrence of AMPK or an item of Supplementary Data 1. The respective
PubMed-IDs were mapped to PMC identifiers using the NCBI E-utilities85 to add
available full texts to the set of relevant documents. This ensured the identification
of relevant events even in the absence of one event partner in the respective
abstract. Identifying any event between genes and proteins was finally
accomplished by employing the BioSem tool86.
Given the BioSem-based reported event set, items that expressed an event
between AMPK and an element of Supplementary Data 1 were filtered. To achieve
this, the initial 204 distinct UniProt IDs delivered by the FASTA entries/
Supplementary Data 1 were mapped to their associated gene names by the
mapping tool ‘UniProt mapping service’ provided at the UniProt website
(http://www.uniprot.org/mapping/). These gene names, in turn, were subsequently
mapped to all associated UniProt identifiers for Homo sapiens and Mus musculus
proteins. This resulted in an extended list of 2,201 UniProt entries (Supplementary
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Data 3, text mining input). For AMPK all UniProt IDs referring to one of its
subunits were collected (Supplementary Data 3, text mining input).
The final filtering was consequently accomplished by restricting the
BioSem-based event set to those, where an AMPK identifier and an identifier of the
extended Supplementary Data 1 and 2 were included (Supplementary Data 3).
Statistics. The number of biological replicates for each experiment is indicated in
the figure legends or methods section. The statistical and programming language R
version 2.15.1 (ref. 87) was used to calculate the statistics and generate the
model perturbation plots, except for Fig. 5i and Supplementary Fig. 23, where
GraphPad Prism Version 5.00 was used to display the quantitations. The s.e.m.
was chosen to estimate the statistical variability of the measured samples of
experimental time course. Statistical significance between control and treatment
in laboratory experimental quantifications was detected by repeated measures
analysis of variance (ANOVA) test implemented in R. Model goodness of fit was
computed using AIC27 as implemented in PottersWheel. Finally, R was also used
for the graphic representation of the identifiability matrix computed with
PottersWheel plugin MOTA.
Data availability. The proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the data set
identifier PXD003073. Other data on which the conclusions of this study are based
are available from the corresponding authors upon request. The three models
generated as a part of this study are provided as Supplementary Softwares:
Supplementary Software 1: SBML model including only the canonical aa input on
mTORC1. Supplementary Software 2: SBML model including four aa inputs in the
network (simple p70-S6K module). Supplementary Software 3: SBML model
similar to Model S2, but including a more complex p70-S6K module.
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